in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
Company profile
Ticker
INAB
Exchange
Website
CEO
William Ho
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Incysus Therapeutics, Inc.
SEC CIK
Corporate docs
IRS number
825462585
INAB stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
14 Mar 24
8-K
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14 Mar 24
S-8
Registration of securities for employees
19 Jan 24
EFFECT
Notice of effectiveness
19 Jan 24
424B3
Prospectus supplement
18 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
S-3
Shelf registration
12 Jan 24
D
$14.43 mm in equity / options, sold $14.43 mm, 20 investors
28 Dec 23
8-K
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
11 Dec 23
Latest ownership filings
SC 13G/A
Ho William Tai-Wei
13 Feb 24
4
Corinne Epperly
8 Feb 24
4
William Tai-Wei Ho
8 Feb 24
4
Trishna Goswami
8 Feb 24
4
Kate Rochlin
8 Feb 24
4
Lawrence Lamb
8 Feb 24
4
Patrick McCall
8 Feb 24
SC 13G/A
Transcend Partners Opportunity Fund I LLC
15 Dec 23
4
Jeremy R. Graff
15 Dec 23
4
Corinne Epperly
15 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.11 mm | 13.11 mm | 13.11 mm | 13.11 mm | 13.11 mm | 13.11 mm |
Cash burn (monthly) | 1.38 mm | 1.23 mm | 2.39 mm | 2.52 mm | 1.90 mm | 2.20 mm |
Cash used (since last report) | 9.46 mm | 8.46 mm | 16.40 mm | 17.27 mm | 13.07 mm | 15.12 mm |
Cash remaining | 3.64 mm | 4.65 mm | -3.29 mm | -4.16 mm | 41.98 k | -2.01 mm |
Runway (months of cash) | 2.6 | 3.8 | -1.4 | -1.7 | 0.0 | -0.9 |
Institutional ownership, Q3 2023
30.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 7 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 2.68 bn |
Total shares | 13.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BIOS Fund II | 6.64 mm | $66.11 mm |
Transcend Partners Opportunity Fund | 4.11 mm | $40.96 mm |
Voss Capital | 511.58 k | $532.05 mm |
Ensign Peak Advisors | 470.03 k | $488.83 mm |
Vanguard | 338.73 k | $352.28 mm |
Sigma Planning | 285.05 k | $296.45 mm |
Geode Capital Management | 188.85 k | $196.46 mm |
Stonegate Investment | 180.00 k | $187.20 mm |
Rock Creek | 151.31 k | $157.37 mm |
Bridgeway Capital Management | 78.30 k | $81.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | Lawrence Lamb | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 169,000 | 206.18 k | 169,000 |
7 Feb 24 | Patrick McCall | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 189,000 | 230.58 k | 189,000 |
7 Feb 24 | Kate Rochlin | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 186,000 | 226.92 k | 186,000 |
7 Feb 24 | Trishna Goswami | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 176,000 | 214.72 k | 176,000 |
7 Feb 24 | William Tai-Wei Ho | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 502,000 | 612.44 k | 502,000 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
12 Apr 24
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
10 Apr 24
Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
10 Apr 24
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
10 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Apr 24
Press releases
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
16 Apr 24
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
9 Apr 24
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14 Mar 24